AMIX Stock Risk & Deep Value Analysis
Autonomix Medical Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About AMIX Stock
We analyzed Autonomix Medical Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran AMIX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
AMIX Risk Analysis & Red Flags
What Could Go Wrong
The company's extremely limited financial resources and current lack of revenue mean it is highly dependent on continuous, dilutive financing rounds. A failure to secure adequate funding or negative clinical trial results would quickly deplete cash and likely lead to insolvency, rendering shares worthless.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Market capitalization listed as $0.00B, indicating an extremely low valuation and high risk of illiquidity/delisting.
- ⚠
No revenue and sustained negative profitability/cash flow, reliant solely on financing for operations.
- ⚠
S-3 shelf registration for 13.5M shares indicates significant potential future dilution.
- ⚠
Lack of analyst coverage and mixed institutional sentiment (some selling noted).
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results
- 📅
Failure to secure additional financing leading to cash depletion
- 📅
Regulatory delays or rejection of applications
When to Reconsider
- 🚪
Exit if no new clinical milestones or financing updates are announced for 6+ months.
- 🚪
Sell if the company announces a capital raise with extreme dilution (>50% of current outstanding shares).
- 🚪
Exit if the share price consistently trades below $0.20 for several weeks.
Unlock AMIX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Autonomix Medical Inc (AMIX) Do?
Market Cap
$4.32M
Sector
Healthcare
Industry
Medical Devices
Employees
8
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Visit Autonomix Medical Inc WebsiteInvestment Thesis
Autonomix Medical Inc. represents an extremely high-risk, high-reward investment opportunity. Its core bull case hinges on the successful clinical development and regulatory approval of its proprietary nerve signal analysis and transvascular RF ablation platform for chronic pain management. Despite severe financial constraints and a precarious cash position, the company's potential to address a large unmet medical need with a novel, differentiated technology could lead to significant market disruption and a substantial re-rating of its valuation if key clinical milestones are achieved, unlocking its 10x growth potential.
Is AMIX Stock Undervalued?
Unlock the full AI analysis for AMIX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
AMIX Price Targets & Strategy
12-Month Target
$3.50
Bull Case
$10.00
Bear Case
$0.05
Valuation Basis
Based on speculative valuation of proprietary nerve signal analysis technology at $150M-$200M (post-mid-stage clinical milestone achievement), assuming ~50M fully diluted shares.
Entry Strategy
Dollar-cost average between $0.30-$0.45, ideally on dips towards the lower end of this range, recognizing the extreme volatility inherent in micro-cap biotechs.
Exit Strategy
Take partial profits at $2.00-$3.00 if clinical milestones are met; implement a tight stop-loss below $0.20 to protect capital.
Portfolio Allocation
7-15% for aggressive risk tolerance; not suitable for moderate or conservative portfolios due to extreme risk.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Does AMIX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat could become durable if the proprietary technology receives regulatory approval and demonstrates superior efficacy and safety in clinical use, creating a unique, protected market position difficult for competitors to replicate without significant R&D investment.
Moat Erosion Risks
- •Failure to secure or defend critical intellectual property rights.
- •Competitors developing alternative or superior nerve targeting/ablation technologies.
- •Clinical trial failures that invalidate the technology's effectiveness.
AMIX Competitive Moat Analysis
Sign up to see competitive advantages
AMIX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish, primarily among highly speculative retail investors, driven by the potential for a breakthrough medical device and 10x returns.
Institutional Sentiment
Neutral/Mixed. While no Form 4s were filed in the last 90 days, Q4 2025 institutional activity showed MARINER LLC selling 47.2% of its position, LPL FINANCIAL LLC making a new small purchase, and IKARIAN CAPITAL LLC selling 6.6%. This indicates some institutions are taking profits or reducing exposure, while others are initiating small, speculative positions.
Insider Activity (Form 4)
No Form 4 filings reported in the last 90 days (Feb 7–May 7, 2026). Institutional changes from Q4 2025 (ended Dec 31, 2025): MARINER LLC sold 47,500 shares (-47.2%, $26,125); LPL FINANCIAL LLC bought 31,435 shares (inf%, $17,289); IKARIAN CAPITAL LLC sold 1,312 shares (-6.6%, $721).
Options Flow
Normal options activity; no unusual or significant institutional options flow reported in the provided research.
Earnings Intelligence
Next Earnings
Estimated mid-May 2026 (for Q1 2026 10-Q)
Surprise Probability
Low (as a pre-revenue company, traditional EPS/revenue surprises are not applicable; focus is on cash burn and clinical updates).
Historical Earnings Pattern
Insufficient historical data as a public entity to establish a meaningful earnings reaction pattern; stock price reaction will be heavily influenced by clinical news and financing updates.
Key Metrics to Watch
Competitive Position
Top Competitor
Nevro Corp (NVRO) or similar neuromodulation/pain management device companies (though AMIX's approach is distinct).
Market Share Trend
Currently has no significant market share; aiming to create a new sub-segment within pain management or medical devices.
Valuation vs Peers
AMIX is a pre-revenue, clinical-stage company trading at an extremely low market cap, making direct traditional valuation comparisons to commercial-stage peers irrelevant. It trades at a deep discount, reflecting its very high risk and early stage.
Competitive Advantages
- •Proprietary nerve signal analysis technology guiding targeted ablation.
- •Potentially less invasive and more precise therapeutic approach for chronic pain.
- •Addressing significant unmet needs, particularly in conditions like pancreatic cancer pain.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive AMIX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 10-Q filing (expected mid-May 2026)
- •Publication of full clinical data from ECIO/DDW presentations (Q2-Q3 2026)
- •Further updates on clinical trial progress or next trial phase initiation (H2 2026)
Medium-Term (6-18 months)
- •Announcement of strategic partnerships or licensing deals (12-18 months)
- •Initiation of pivotal (Phase 2/3 or Phase 3) clinical trials (12-18 months)
- •Expansion into additional pain management indications (18-24 months)
Long-Term (18+ months)
- •Regulatory submission for market approval (24-36 months)
- •Commercial launch and market adoption of nerve signal analysis platform (36-48 months)
- •Disruption of legacy chronic pain treatment markets (3-5 years)
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for AMIX?
- ✓
Acceleration in clinical trial progress, particularly the initiation or positive readouts of pivotal trials.
- ✓
Successful, non-dilutive financing rounds or strategic partnership announcements.
- ✓
Clear guidance on pathways to regulatory approval and commercialization.
Bull Case Analysis
Sign up free to see the bull case
Competing with AMIX
See how Autonomix Medical Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Autonomix Medical Inc AMIX | $4.3M | 5.3 | — | — | — | — | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Autonomix Medical Inc Makes Money
Autonomix Medical Inc. is a clinical-stage medical technology company developing a proprietary platform centered around nerve signal analysis to guide minimally invasive interventional therapies. Their primary aim is to commercialize specialized medical devices and associated single-use consumables that enable precise nerve targeting and ablation, initially focusing on alleviating chronic pain such as that associated with pancreatic cancer. Revenue generation is anticipated to begin post-regulatory approval through direct sales to hospitals and pain clinics, or potentially via licensing agreements with larger medical device or pharmaceutical companies.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Autonomix Medical Inc (AMIX)?
As of May 7, 2026, Autonomix Medical Inc has a DVR Score of 5.3 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Autonomix Medical Inc?
Autonomix Medical Inc's market capitalization is approximately $4.3M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Autonomix Medical Inc use?
AMIX is the ticker symbol for Autonomix Medical Inc. The company trades on the NCM.
What is the risk level for AMIX stock?
Our analysis rates Autonomix Medical Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the AMIX DVR analysis updated?
Our AI-powered analysis of Autonomix Medical Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 7, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for AMIX (Autonomix Medical Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.